Fate Therapeutics Inc
NASDAQ:FATE
Fate Therapeutics Inc
NASDAQ:FATE
Price:
3.68 USD
-3.16%
Market Closed
Updated:
Jun 8, 2024
Fate Therapeutics Inc
Stock-Based Compensation
|
Fate Therapeutics Inc
Stock-Based Compensation Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Stock-Based Compensation Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fate Therapeutics Inc
NASDAQ:FATE
|
Stock-Based Compensation
$43.5m
|
CAGR 3-Years
6%
|
CAGR 5-Years
38%
|
CAGR 10-Years
34%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$782m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
$788m
|
CAGR 3-Years
7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$650.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
16%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Fate Therapeutics Inc's Stock-Based Compensation?
Stock-Based Compensation
43.5m
USD
43.5m
USD
Based on the financial report for Mar 31, 2024, Fate Therapeutics Inc's Stock-Based Compensation amounts to 43.5m USD.
What is Fate Therapeutics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
34%
34%
Over the last year, the Stock-Based Compensation growth was -38%. The average annual Stock-Based Compensation growth rates for Fate Therapeutics Inc have been 6% over the past three years , 38% over the past five years , and 34% over the past ten years .
You don't have any saved screeners yet
